A phase I study of subcutaneous 'CYT 107' (interleukin 7) in refractory metastatic melanoma or renal cell carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2012
At a glance
- Drugs Interleukin-7 (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 25 Jul 2012 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
- 01 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.